‘AI will assist in creating a personalized experience for each individual,’ says Alexey Gubarev

AI assistance will play a significant role.
Alexey Gubarev is a multifaceted individual, serving as an entrepreneur, investor, and philanthropist, with an unwavering dedication to Cyprus. His visionary leadership has played a pivotal role in the transformation of Cyprus into a recognized tech hub. Read on to know his thoughts about innovative technologies and its impact on future of healthcare industry.

I believe it's essential to ensure that every position within the company is filled by qualified individuals who can effectively manage teams and deliver results.

Media 7: Please tell us something about your journey. You've been involved in various tech-related roles; how have those experiences influenced your approach as a leader and board member of leading companies?
Alexey Gubarev:
I began my journey in the internet business at the end of the 1990s, around the turn of the century. In 2002, I relocated to Cyprus with my family and my wife. In 2005, me and my two friends established our first company, which eventually evolved into Servers.com, our first major venture in the cloud industry.

When we initially launched the company with a team of five, I assumed the role of Operational Sales Director. Eventually, as the company grew, I found myself serving as a CEO in this capacity for 13 years. I was responsible for overseeing various aspects of the business, essentially becoming the backbone of the company. Notably, I wasn't just the Chief Executive Officer; I was also one of the primary shareholders from the very beginning. This made our situation quite unique; we never sought external capital, and the individuals who initially founded the company also became its primary investors. It was an unconventional setup, but it worked for us. Essentially, we managed to achieve profitability from day one. For many years, we reinvested all our profits back into the business, allowing it to flourish. The fruits of this endeavor culminated in.

A few years before I resigned the CEO position at Servers.com, I made a decision to invest in startups. My first notable investment was in the famous startup Prisma. This was during its peak popularity in 2016, when it became the number one application according to Google and Apple, with over 120 million downloads in a single year.

In 2016, we established the eventual parent company, Palta, as a means to consolidate our investments in various types of applications under one umbrella. This startup venture proved to be quite successful. Currently, our applications boast over 56 million monthly users and more than 5 million subscribers. Our company now employs over 800 people.

M7: Given your role as a co-founder across three organizations, your wealth of experience in running companies is evident. Could you elaborate on your approach to delegation and perhaps share an illustrative instance where your leadership contributed to a company’s growth through acquisitions or partnerships?
AG:
Okay, at Servers.com, I was responsible for sales, and I managed a team that handled several hundred clients. I focused primarily on B2B sales, and it played a significant role in the company.

While sales were crucial, obtaining B2B customers was our top priority, and I excelled in that area. When we initially started the company from scratch, within just six years, we had already generated over $30 million in revenue.

Now, let's talk about leadership within the company, which centers around the individuals working alongside you, day in and day out. This was a key aspect for me. I believe it's essential to ensure that every position within the company is filled by qualified individuals who can effectively manage teams and deliver results.

In the companies we've built, the team has played a significant role in our success. We've had many team members who have stayed with us for many years. This helped us establish several successful companies in a relatively short span of time.

Personally, when it comes to my strengths, I excel in sales and operations. I have a knack for problem-solving, regardless of the region or circumstances. Additionally, I'm adept at making rapid decisions, even when facing hundreds of choices in a single day. I've applied these skills across various companies and situations over time.

M7: Would you like to share the key challenges and milestones as a co-founder of a health tech startup?
AG:
I firmly believe that the most significant challenge lies in market fit. Simply having an idea, no matter how brilliant it may be, doesn't guarantee success unless it's embraced by the market. Over time, we've observed that some companies achieve immediate success because their ideas resonate right from the start. However, for others, it can take one, two, or even three years to truly discover the right product fit. Even if you have a great product idea within a niche market, it's crucial to understand the final product that people will actually use and be willing to consume on a regular basis. The ultimate success of any startup hinges on its audience and how well you can capture and retain them as users of your product. This is our primary focus; we want our products, regardless of their nature, to be genuinely useful to people.

Read more: 'AI is only as smart as the data and the people behind it', says Kyle Ryan 


The ultimate success of any startup hinges on its audience and how well you can capture and retain them as users of your product.

M7: In your opinion, how do content creation, syndication and advertising contribute to the overall success of an organization in terms of brand awareness?
 AG:
Let’s speak about what content is. In an application like Flo, the content consists of articles and helpful information curated for women—that's one content category. Now, let's shift our focus to another type of content in an application like Lensa, which is primarily a photo and video editor. In this case, content involves filters and visual elements. It's a different kind of content because it caters to the specific needs of the users, allowing them to transform their photos in unique ways. Content within an application can vary significantly depending on its nature. It's not just about the information you provide but also about the actions users can take.

Speaking of marketing, there have been significant changes in marketing strategies over the past seven years. We've seen very few products on the market that have been successful without relying on performance marketing. This has presented a considerable challenge. For example, last year, our application Lensa achieved significant success, becoming the number one application worldwide in December 2022. This was a period when we had the opportunity to gain organic traction as people were actively discussing the app. However, achieving such results has become increasingly rare.

It's essential to understand that in today's market, performance marketing is the key to acquiring customers. You need to be effective with your marketing spend, ensuring that the money invested in advertising brings tangible value. Gone are the days when startups could simply acquire a user base without immediate consideration of financial results. Now, it's all about acquiring users while simultaneously generating a positive financial outcome. Your financial performance must cover marketing costs and more. Investors have become more cautious and demand a clearer path to profitability before committing substantial investments. They no longer throw billions of dollars into a project with the hope of future success.

M7: Can you discuss any innovative technologies that you believe will significantly impact the future of health technology?
AG:
In the realm of health technology, we firmly believe that AI assistance will play a significant role. A case in point is the progress we've seen with advanced models like Chat GPT and Facebook's LLaMA, which were recently released.

It's an exceedingly effective means of communication for people, and it's not just our opinion; the market shares this sentiment. I've noticed a shift in preference from voice-based interactions to text-based ones. Many responses are now generated by AI, and this reflects the direction we're headed. Naturally, it will require some time and a focus on delivering precise answers, especially on specific topics, without touching sensitive information. Nevertheless, it's progressing well in providing users with the information they seek.

This is why we believe AI will shape the future. The conventional approach of navigating through applications with buttons and menus has, in my opinion, become too complex for users. People now prefer having a chat-like interface where they can engage in conversation to obtain the information they desire. It's akin to having a personal friend, whether it's for your personal well-being or academic pursuits. It's about having someone who possesses substantial knowledge about your strengths and weaknesses and guides you in areas that require focus. For example, if you struggle with certain exercises, having AI that understands this and can provide tailored advice to help you improve is invaluable. In one of our applications, Zing, we've even introduced a specialized system where your phone monitors your exercise performance, offering real-time feedback. It simplifies the process, making it more accessible.

The distinguishing factor here is personality. Currently, most applications treat users uniformly and lack personalization. However, I believe that in the future, AI will assist in creating a personalized experience for each individual, catering to their unique needs and preferences.

Read more: Q&A with Matthew Sappern, CEO at PeriGen


It's not just about the information you provide but also about the actions users can take.

M7: Funding is a crucial aspect of startup growth. Can you discuss your experience in securing funding and any advice you have for other health tech entrepreneurs seeking investment?
AG:
Now, it's a challenging period to raise capital, which is something every digital company, regardless of its size, must grasp. Often, many people find it extremely difficult, especially when they are far removed from the market or distant from potential investors.

What I believe is essential, depending on the stage you are at, is to clearly communicate and present to your investors when you expect to generate revenue and achieve possible break-even points. Additionally, your marketing model should be cost-effective from the outset. You can't afford to spend money now and hope to recoup it from customers three or four years down the line. You need to ensure that your marketing investments yield returns relatively quickly, typically within one to two years. We no longer have the luxury of extravagant budgets and prolonged spending.

Equally important is having a strong and efficient team. Effectiveness hinges on how well you manage your spending and deliver on your plans. Based on my personal experience, most startups, even those with brilliant ideas, often struggle to gain the trust of potential investors. This is a significant challenge that underscores the importance of consistency. Sometimes, it's better to be a bit more conservative in your projections and present a more realistic picture.
 
It's amusing, especially when you're just starting with an idea, to present your vision precisely. However, it's crucial to understand that in the initial stages, discussing revenue and profitability might not be relevant. Instead, focus on elements like market size and other key factors pertinent to your current stage. Startups must recognize the importance of concentrating on each stage's specific priorities.

Finally, after finding the perfect product, gaining attention through marketing, and establishing a successful business model, you must be precise about your actions. Avoid painting an overly optimistic picture, as it's often unconvincing to potential investors.

M7: What strategies and initiatives does your non-profit organization employ to fulfill its vision of transforming Cyprus into the leading tech hub of Europe?
AG:
Okay, I co-founded the largest association of IT companies in Cyprus, TechIsland, which is a truly unique example. There's no other company or organization with such a wide scope and impact. This has been my passion for many years, and it's why I've dedicated a significant part of my career to it.

In 2020, we had the opportunity to engage with the government and discuss the potential future of the IT sector in Cyprus. It was in 2021 that we officially established the organization with a growing number of members, including both companies and supportive government initiatives. The goal was to explore how Cyprus could contribute to the future of this industry.

Our efforts proved successful. In 2020, the ICT sector's contribution to the GDP was 8.5%, and by 2022, it had nearly doubled up to 13%. This serves as an excellent example of private sector initiatives working hand in hand with the government to attract more companies to the region. When we started, we were just a few people, but now we have 290 member companies, and the number of people working in the ICT sector in Cyprus, specifically in our organization, is around 25,000, and it's growing every day.

We believe that the ICT sector has a bright future in Cyprus. We have a vision, and with the right approach, the right message, and the support of our community, as well as government officials who have been instrumental in our success, we aim to make the ICT sector a key driver of Cyprus's economy in the next five years. 

ABOUT PALTA

Palta is a dynamic collective of Wellbeing and HealthTech brands. It collaborate with visionary entrepreneurs and exceptional individuals to translate groundbreaking concepts into life-enhancing applications that create a meaningful global influence. With a team of more than 700 professionals, it's presence spans across offices in the UK, US, EU, and Israel. To know more please visit; https://palta.com/.

More C-Suite on deck

James Bates on Shifting Perspectives: From AI as a Job Threat to AI as a Vital Workforce Aid in Healthcare

Media 7 | October 19, 2023

Step into the transformative world of healthcare with James Bates, an accomplished CEO, entrepreneur, and board member who has driven high-growth plans for leading technology companies. As the Chairman and Founder of AdviNow Medical, James has conceptualized a groundbreaking vision, raised capital, and launched the world's first Artificial Intelligence and Augmented Reality-driven automated medical visit system. Join us for an illuminating conversation with James Bates, a visionary leader in healthcare technology.

Read More

'AI is only as smart as the data and the people behind it', says Kyle Ryan

Media 7 | May 17, 2023

Kyle Ryan believes that innovative concepts, data-driven insights, precise engineering, and efficient execution combine to create great products. He also believes that leadership is essential for innovation. Read on to know his thoughts on the role of leadership and technology in healthcare industry.

Read More

Q&A with Matthew Sappern, CEO at PeriGen

Media 7 | September 30, 2021

Matthew Sappern, CEO at PeriGen, had served as a corporate officer for Eclipsys Corporation before and during its merger with Allscripts. Leading up to the merger, Sappern served as Eclipsys Senior Vice President of Professional Services, responsible for the company’s $100M consulting, implementation and training P&L. Sappern joined Eclipsys in January 2003, as VP of product development in the software engineering division. Over a time of three years, he came to run 75 percent of the development operation and oversaw the delivery of three critical enterprise software releases in record time for the company.

Read More

James Bates on Shifting Perspectives: From AI as a Job Threat to AI as a Vital Workforce Aid in Healthcare

Media 7 | October 19, 2023

Step into the transformative world of healthcare with James Bates, an accomplished CEO, entrepreneur, and board member who has driven high-growth plans for leading technology companies. As the Chairman and Founder of AdviNow Medical, James has conceptualized a groundbreaking vision, raised capital, and launched the world's first Artificial Intelligence and Augmented Reality-driven automated medical visit system. Join us for an illuminating conversation with James Bates, a visionary leader in healthcare technology.

Read More

'AI is only as smart as the data and the people behind it', says Kyle Ryan

Media 7 | May 17, 2023

Kyle Ryan believes that innovative concepts, data-driven insights, precise engineering, and efficient execution combine to create great products. He also believes that leadership is essential for innovation. Read on to know his thoughts on the role of leadership and technology in healthcare industry.

Read More

Q&A with Matthew Sappern, CEO at PeriGen

Media 7 | September 30, 2021

Matthew Sappern, CEO at PeriGen, had served as a corporate officer for Eclipsys Corporation before and during its merger with Allscripts. Leading up to the merger, Sappern served as Eclipsys Senior Vice President of Professional Services, responsible for the company’s $100M consulting, implementation and training P&L. Sappern joined Eclipsys in January 2003, as VP of product development in the software engineering division. Over a time of three years, he came to run 75 percent of the development operation and oversaw the delivery of three critical enterprise software releases in record time for the company.

Read More

Related News

Health Technology

PureHealth Completes Acquisition of UK’s Largest Private Healthcare Group

PureHealth | January 16, 2024

PureHealth, the largest healthcare platform in the Middle East, has announced the successful completion of its strategic acquisition of Circle Health Group, UK’s largest independent operators of hospitals, marking a significant milestone in the company's global expansion strategy. The completion of this deal, which has achieved regulatory approvals in record time, signifies PureHealth’s exceptional operational capabilities and commitment to international growth. The completion of this transaction further strengthens PureHealth’s commitment to becoming a leading global player in healthcare. With a vision aligned with the UAE leadership to promote wellbeing and enhance healthcare services, PureHealth is dedicated to continuously improving patient experience and adopting the most advanced clinical practices. The company’s expansion into the UK healthcare market reflects its focus on advancing the science of longevity and unlocking time for humanity. Hamad Al Hammadi, Chairman of the Board of Directors of PureHealth, said: “We are pleased to complete the acquisition of Circle in record time. This remarkable achievement epitomises PureHealth's operational excellence and strategic adaptability in broadening its international impact. After investing in Ardent Health USA, this is PureHealth’s second international acquisition, and we look forward to building our portfolio internationally.” Farhan Malik, Founder and Managing Director of PureHealth, commented: “Completing the acquisition of Circle is a strategic leap forward for PureHealth. This acquisition is more than an expansion; it's a significant stride towards establishing PureHealth as a global healthcare platform. We are not just investing in the future of healthcare; we are shaping it to be more connected, innovative, and accessible on a global scale. This move aligns with our vision of pioneering a healthier future for all and underscores our commitment to elevating the global position of Abu Dhabi in the healthcare sector and revolutionising healthcare services globally. We look forward to fostering long term partnerships within the UK’s healthcare ecosystem.” Valued at c.USD 1.2 billion before debt, this acquisition marks a significant investment in the future of healthcare, positioning PureHealth at the forefront of international healthcare innovation and service provision. Building upon this significant momentum, PureHealth is advancing its expansion strategy in 2024. This strategic vision includes not only acquisitions in locally, but also international markets building a global healthcare platform. As PureHealth moves forward with its strategic global expansion, it remains committed to its mission of delivering unrivalled healthcare experiences through innovation, technology-driven solutions, and collaboration. This transaction not only enhances PureHealth's services and presence in the international healthcare landscape but also solidifies the company’s position as a leader in the healthcare industry, dedicated to improving lives and fostering healthier communities worldwide, and taking PureHealth from Abu Dhabi to the World. About PureHealth By advancing the Science of Longevity, PureHealth is introducing the healthcare of the future from the United Arab Emirates to the rest of the world. PureHealth is the largest healthcare platform in the Middle East with an ecosystem that challenges lifespans and reimagines health spans. With 25+ hospitals, 100+ clinics, multiple diagnostic centres, health insurance solutions, pharmacies, health tech, procurement, investments and more. With groundbreaking innovations at the forefront of healthcare, the company is on a mission to unlock time for humankind.

Read More

Health Technology

Beckman Coulter Unveils DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance

Beckman Coulter Diagnostics | January 30, 2024

Beckman Coulter Diagnostics, a clinical diagnostics leader, will unveil its new DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer, at Medlab Middle East in Dubai, taking place February 5-8, 2024. The DxC 500 AU Chemistry Analyzer is one of several recent Beckman Coulter solutions designed to address the complete needs of healthcare systems that are looking to complement central hub laboratories by advancing the technology and capabilities of satellite and independent hospital laboratories. "Healthcare systems around the world are strategically adopting hub-and-spoke models for better efficiency and healthcare access," said Kathleen Orland, Senior Vice President, Business Unit, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics. "Hub-and-spoke clinical laboratory models optimize resources to improve access to testing services and enhance overall standardization for quality testing and positive impact on inventory and cost management across a health system. The new DxC 500 AU Chemistry Analyzer advances capabilities of spoked labs with a broad menu of high-quality assays that deliver consistent, commutable results across Beckman Coulter's AU clinical chemistry systems, positively impacting clinical decision-making and patient outcomes." The DxC 500 AU Chemistry Analyzer features advanced automation technology, onboard guided workflows, and standardized reagents for use across healthcare networks. Its menu of more than 120 assays has been independently and objectively verified for high quality Six Sigma performance, supporting confidence in clinical results, reducing QC trouble shooting and lab operational costs. "Our Six Sigma assessment has shown that the DxC 500 AU analyzer easily exceeds the demands of the new, more stringent CLIA 2024 performance specifications," stated Sten Westgard, Director of Client Services and Technology for Westgard QC. The DxC 500 AU Chemistry Analyzer is for in vitro diagnostic use only. It is available throughout North America and the Middle East. Global commercial availability is planned for March 2024. About Beckman Coulter. Inc. A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory's role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what's now to what's next. We seek to accelerate care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Headquartered in Brea, Calif., with more than 11,000 global team members, Beckman Coulter Diagnostics is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. ©2024 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Read More

Healthcare Analytics

SHL Medical partners with SteriPack Group to set up final assembly service

SHL Medical | January 24, 2024

SHL Medical, a world-leading solutions provider of advanced drug delivery systems and SteriPack Group, renowned global supplier of secondary packing and final assembly services to the pharmaceutical industry, enter a non-exclusive strategic partnership. Together, they aim to establish a pre-validated final assembly service at the SteriPack facility in Poland, enhancing the overall flexibility of supply chain strategies for their customers. In addition to SHL Medical's existing final assembly, labeling, and packaging­ services in the United States, this collaboration extends high-quality CMO options to Europe. Markus Puusepp, SHL Medical's Chief Growth Officer, expressed enthusiasm about the partnership, stating "This partnership is a significant addition to the Molly® platform value proposition. We share common values with SteriPack, from focus on the customer to a commitment to quality, making the decision to collaborate straightforward." Recognizing the importance of flexibility and time-to-market, especially in clinical production, the partnership with SteriPack will offer SHL Medical's customers highly flexible and personalized final assembly and packaging solutions. This is particularly beneficial for small batch handling in clinical supply and niche markets like rare diseases. Emphasizing the comprehensive capabilities of the Molly platform, SHL Medical aims to deliver right-sized solutions that ensure improved service, faster timelines, and a more streamlined supply chain for its diverse customer base. John Ward, SteriPack Group's VP Pharmaceutical Solutions commented "SteriPack Group looks forward to supporting SHL Medical and their customers in providing quality and flexible solutions to a fast- moving market. With an emphasis on creating service solutions designed around specific customer requirements, this partnership will make the process of working with the Molly® platform an easy decision." About SHL Medical As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose – Enabling Patients' Independence – SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems. In response to the rising trend in home therapy, SHL Medical has increased its developmental work in the digital healthcare sector to help improve the drug delivery ecosystem. Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical's global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth. About SteriPack Group SteriPack Group is a globally renowned contract packing and manufacturing organisation serving the pharmaceutical and medical device sectors respectively. With a strong emphasis on innovation, quality and compliance, SteriPack's services to the pharmaceutical industry include device design and development, final assembly, labelling, secondary packing, serialisation and aggregation of injectable formats including vials, pre-filled syringes, and autoinjectors. SteriPack's tailored customer-focused solutions make it an ideally suited supplier for small to medium-sized batch volumes required for a growing market of targeted therapies as well as clinical trials. Its proven capabilities in cleanroom assembly and labelling as well as secondary packing services for drug delivery systems and medical devices, combined with significant investment into growing cold chain storage capacity, have helped to make it a trusted partner to top global pharmaceutical companies.

Read More

Health Technology

PureHealth Completes Acquisition of UK’s Largest Private Healthcare Group

PureHealth | January 16, 2024

PureHealth, the largest healthcare platform in the Middle East, has announced the successful completion of its strategic acquisition of Circle Health Group, UK’s largest independent operators of hospitals, marking a significant milestone in the company's global expansion strategy. The completion of this deal, which has achieved regulatory approvals in record time, signifies PureHealth’s exceptional operational capabilities and commitment to international growth. The completion of this transaction further strengthens PureHealth’s commitment to becoming a leading global player in healthcare. With a vision aligned with the UAE leadership to promote wellbeing and enhance healthcare services, PureHealth is dedicated to continuously improving patient experience and adopting the most advanced clinical practices. The company’s expansion into the UK healthcare market reflects its focus on advancing the science of longevity and unlocking time for humanity. Hamad Al Hammadi, Chairman of the Board of Directors of PureHealth, said: “We are pleased to complete the acquisition of Circle in record time. This remarkable achievement epitomises PureHealth's operational excellence and strategic adaptability in broadening its international impact. After investing in Ardent Health USA, this is PureHealth’s second international acquisition, and we look forward to building our portfolio internationally.” Farhan Malik, Founder and Managing Director of PureHealth, commented: “Completing the acquisition of Circle is a strategic leap forward for PureHealth. This acquisition is more than an expansion; it's a significant stride towards establishing PureHealth as a global healthcare platform. We are not just investing in the future of healthcare; we are shaping it to be more connected, innovative, and accessible on a global scale. This move aligns with our vision of pioneering a healthier future for all and underscores our commitment to elevating the global position of Abu Dhabi in the healthcare sector and revolutionising healthcare services globally. We look forward to fostering long term partnerships within the UK’s healthcare ecosystem.” Valued at c.USD 1.2 billion before debt, this acquisition marks a significant investment in the future of healthcare, positioning PureHealth at the forefront of international healthcare innovation and service provision. Building upon this significant momentum, PureHealth is advancing its expansion strategy in 2024. This strategic vision includes not only acquisitions in locally, but also international markets building a global healthcare platform. As PureHealth moves forward with its strategic global expansion, it remains committed to its mission of delivering unrivalled healthcare experiences through innovation, technology-driven solutions, and collaboration. This transaction not only enhances PureHealth's services and presence in the international healthcare landscape but also solidifies the company’s position as a leader in the healthcare industry, dedicated to improving lives and fostering healthier communities worldwide, and taking PureHealth from Abu Dhabi to the World. About PureHealth By advancing the Science of Longevity, PureHealth is introducing the healthcare of the future from the United Arab Emirates to the rest of the world. PureHealth is the largest healthcare platform in the Middle East with an ecosystem that challenges lifespans and reimagines health spans. With 25+ hospitals, 100+ clinics, multiple diagnostic centres, health insurance solutions, pharmacies, health tech, procurement, investments and more. With groundbreaking innovations at the forefront of healthcare, the company is on a mission to unlock time for humankind.

Read More

Health Technology

Beckman Coulter Unveils DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance

Beckman Coulter Diagnostics | January 30, 2024

Beckman Coulter Diagnostics, a clinical diagnostics leader, will unveil its new DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer, at Medlab Middle East in Dubai, taking place February 5-8, 2024. The DxC 500 AU Chemistry Analyzer is one of several recent Beckman Coulter solutions designed to address the complete needs of healthcare systems that are looking to complement central hub laboratories by advancing the technology and capabilities of satellite and independent hospital laboratories. "Healthcare systems around the world are strategically adopting hub-and-spoke models for better efficiency and healthcare access," said Kathleen Orland, Senior Vice President, Business Unit, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics. "Hub-and-spoke clinical laboratory models optimize resources to improve access to testing services and enhance overall standardization for quality testing and positive impact on inventory and cost management across a health system. The new DxC 500 AU Chemistry Analyzer advances capabilities of spoked labs with a broad menu of high-quality assays that deliver consistent, commutable results across Beckman Coulter's AU clinical chemistry systems, positively impacting clinical decision-making and patient outcomes." The DxC 500 AU Chemistry Analyzer features advanced automation technology, onboard guided workflows, and standardized reagents for use across healthcare networks. Its menu of more than 120 assays has been independently and objectively verified for high quality Six Sigma performance, supporting confidence in clinical results, reducing QC trouble shooting and lab operational costs. "Our Six Sigma assessment has shown that the DxC 500 AU analyzer easily exceeds the demands of the new, more stringent CLIA 2024 performance specifications," stated Sten Westgard, Director of Client Services and Technology for Westgard QC. The DxC 500 AU Chemistry Analyzer is for in vitro diagnostic use only. It is available throughout North America and the Middle East. Global commercial availability is planned for March 2024. About Beckman Coulter. Inc. A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory's role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what's now to what's next. We seek to accelerate care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Headquartered in Brea, Calif., with more than 11,000 global team members, Beckman Coulter Diagnostics is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. ©2024 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Read More

Healthcare Analytics

SHL Medical partners with SteriPack Group to set up final assembly service

SHL Medical | January 24, 2024

SHL Medical, a world-leading solutions provider of advanced drug delivery systems and SteriPack Group, renowned global supplier of secondary packing and final assembly services to the pharmaceutical industry, enter a non-exclusive strategic partnership. Together, they aim to establish a pre-validated final assembly service at the SteriPack facility in Poland, enhancing the overall flexibility of supply chain strategies for their customers. In addition to SHL Medical's existing final assembly, labeling, and packaging­ services in the United States, this collaboration extends high-quality CMO options to Europe. Markus Puusepp, SHL Medical's Chief Growth Officer, expressed enthusiasm about the partnership, stating "This partnership is a significant addition to the Molly® platform value proposition. We share common values with SteriPack, from focus on the customer to a commitment to quality, making the decision to collaborate straightforward." Recognizing the importance of flexibility and time-to-market, especially in clinical production, the partnership with SteriPack will offer SHL Medical's customers highly flexible and personalized final assembly and packaging solutions. This is particularly beneficial for small batch handling in clinical supply and niche markets like rare diseases. Emphasizing the comprehensive capabilities of the Molly platform, SHL Medical aims to deliver right-sized solutions that ensure improved service, faster timelines, and a more streamlined supply chain for its diverse customer base. John Ward, SteriPack Group's VP Pharmaceutical Solutions commented "SteriPack Group looks forward to supporting SHL Medical and their customers in providing quality and flexible solutions to a fast- moving market. With an emphasis on creating service solutions designed around specific customer requirements, this partnership will make the process of working with the Molly® platform an easy decision." About SHL Medical As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose – Enabling Patients' Independence – SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems. In response to the rising trend in home therapy, SHL Medical has increased its developmental work in the digital healthcare sector to help improve the drug delivery ecosystem. Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical's global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth. About SteriPack Group SteriPack Group is a globally renowned contract packing and manufacturing organisation serving the pharmaceutical and medical device sectors respectively. With a strong emphasis on innovation, quality and compliance, SteriPack's services to the pharmaceutical industry include device design and development, final assembly, labelling, secondary packing, serialisation and aggregation of injectable formats including vials, pre-filled syringes, and autoinjectors. SteriPack's tailored customer-focused solutions make it an ideally suited supplier for small to medium-sized batch volumes required for a growing market of targeted therapies as well as clinical trials. Its proven capabilities in cleanroom assembly and labelling as well as secondary packing services for drug delivery systems and medical devices, combined with significant investment into growing cold chain storage capacity, have helped to make it a trusted partner to top global pharmaceutical companies.

Read More